Vaccine Effects on In-hospital COVID-19 Outcomes
- PMID: 40525720
- PMCID: PMC12303245
- DOI: 10.1097/EDE.0000000000001877
Vaccine Effects on In-hospital COVID-19 Outcomes
Abstract
Here, we posit that studies comparing outcomes of patients hospitalized with COVID-19 by vaccination status are important descriptive epidemiologic studies, but they contrast two groups that are not comparable with regard to causal analyses. We use the principal stratification framework to show that these studies can estimate a causal vaccine effect only for the subgroup of individuals who would be hospitalized with or without vaccination. Further, we describe the methodology for, and present sensitivity analyses of, this effect. Using this approach can change the interpretation of studies only reporting the standard analyses that condition on observed hospital admission status-that is, analyses comparing outcomes for all hospitalized COVID-19 patients by vaccination status.
Keywords: Causal inference; Disease progression; Post-treatment variable; Potential outcomes; Principal stratification; Vaccination.
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
B.J.C. consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur. All other authors report no conflicts of interests.
Figures

Similar articles
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
-
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2023 Nov 30;11:CD015395. doi: 10.1002/14651858.CD015395.pub3. PMID: 36126225 Free PMC article. Updated.
-
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3. Cochrane Database Syst Rev. 2023. PMID: 38032024 Free PMC article.
-
Vaccines for preventing infections in adults with haematological malignancies.Cochrane Database Syst Rev. 2025 May 21;5(5):CD015530. doi: 10.1002/14651858.CD015530.pub2. Cochrane Database Syst Rev. 2025. PMID: 40396505 Review.
References
-
- Modes ME, Directo MP, Melgar M, et al. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:217–223. - PMC - PubMed
-
- Whittaker R, Bråthen Kristofferson A, Valcarcel Salamanca B, et al. Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients. Clin Microbiol Infect. 2022;28:871–878. - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical